News & Updates

Use of sphingosine 1-phosphate receptor modulators (S1PRM) demonstrates safety and efficacy in the treatment of moderate-to-severe ulcerative colitis (UC), results of a recent study have shown.

A low-protein diet (LPD) combined with physical exercise provides significant benefits to patients with chronic kidney disease (CKD) by lowering blood pressure (BP) and improving glomerular filtration and cardiopulmonary function status, a study has shown.

The risk of malignant progression in individuals with Barrett’s esophagus appears to be heightened among those with obesity, with the risk increase commensurate with BMI, according to the results of a meta-analysis.

Induction and maintenance treatment with risankizumab significantly improved the rates of clinical remission in adults with moderate-to-severe active ulcerative colitis (UC), according to two phase III randomized clinical trials.

Endoscopic ultrasound (US)-guided rendezvous (EUS-RV) technique is on a par with precut sphincterotomy as a salvage technique for patients with difficult bile duct cannulation for benign biliary disease, a study has shown. The complications rates for the two approaches are both acceptable.

Surgeons at the Chinese University of Hong Kong (CUHK) and the Swiss Federal Institute of Technology Zurich (ETH Zurich) have become the first in the world to perform teleoperated magnetic endoscopy in a porcine model across a distance of 9,300 km.

A safety signal for acute pancreatitis among users of the calcineurin inhibitor (CNI) tacrolimus has been identified in an observational retrospective pharmacovigilance study.

Treatment with liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX) improved overall survival (OS) and progression-free survival (PFS) in patients aged ≥65 years with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP), according to a post hoc analysis of the phase III NAPOLI 3 trial presented at ESMO GI 2024.

New drug applications approved by US FDA as of 1-15 August 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.